Piramal’s Sensipar Generic Blocked In US, For Now

 
• By Anju Ghangurde and Sue Sutter

Piramal halted sales of its generic version of Amgen’s Sensipar following a US court order that also required Amgen to furnish a $39m bond. The Sensipar generic launch landscape continues to be complex with multiple legal challenges, including those from Cipla and Sun at various stages.

Labyrinth
MULTIPLE CHALLENGES DOT THE SENSIPAR GENERIC LAUNCH LANDSCAPE

More from Legal & IP

More from Business